ArticleAnnals of medicine2025
Incidence and risk factors of abnormal liver function and anti-tuberculosis drug-induced liver injury: a multicenter retrospective study involving 482 chinese pediatric tuberculosis patients.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for drug-induced liver injury in tuberculosis patients: a meta-analysis and systematic review.Frontiers in medicine · 2026Pooled it
- NAT2 rs1495741 and anti-tuberculosis drug-induced liver injury in children: genetic association and risk prediction.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the incidence of abnormal liver function, which can lead to serious consequences, as well as anti-tuberculosis drug-induced liver injury (ATDILI) and their associated risk factors.
methodsA national multicenter retrospective study was conducted to collected pediatric TB treatment data from 11 specialized and general hospitals. The multivariate logistic regression analysis was performed to assess the influencing factors of abnormal liver function and ATDILI. The Kaplan-Meier survival analysis assessed temporal risk trends for these outcomes.
resultsAmong the 482 patients included in the study, 18 patients (3.73%) experienced ATDILI, and 51 (10.58%) experienced abnormal liver function. The time of occurrence of abnormal liver function and ATDILI was 20.0 (IQR: 6.0, 34.0) days and 28.0 (IQR: 8.0, 87.0) days, respectively. The multivariate analysis results showed that, patients who used second line drugs in the intensive phase were more likely to experience ATDILI (OR = 4.16, 95% CI: 1.34 ∼ 12.84,
conclusionThe incidence of abnormal liver function and ATDILI differed. By considering laboratory indicators and clinical practice, early identification and detection of abnormal liver function in children during anti-TB treatment, along with timely intervention, can effectively prevent and control the harm caused by abnormal liver function and prevent it progression to ATDILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.